Immunocore Presents Single Agent IMCgp100 data in Metastatic Uveal Melanoma Showing Durability, Doubling in One-Year Overall Survival Rate
Immunocore’s intra-patient dose escalation Phase I IMCgp100 study in metastatic uveal melanoma patients demonstrates a one-year overall survival (OS) rate of 73% (95% confidence interval [46, 88]) and a one-year progression-free-survival (PFS) rate of 62% based on the irRC criteria as of the data cut-off in October 2017. Median OS has not been reached with median follow-up of 12.8 months in this cohort. The overall survival data from this study compare very favourably to studies with other agents, which show one-year OS rates of approximately 25-45%.*
For the full press release: http://glassdoor.com/slink.htm?key=vQDGT
We're world leading and at the cutting edge of some highly sophisticated stuff! ImmTAC molecules are a new class of bi-specific biologic molecules that combine an affinity-enhanced T cell receptor (TCR)-based targeting system with an anti-CD3 (scFv) effector function to activate a highly potent and specific T cell response to recognise and destroy cancer cells.
Ultimately, our work here is about transforming the lives of patients, their families and the wider scientific and medical communities.
We're a very active bunch in all sorts of ways; the sport and social committee are always busy, keeping us... busy. Whether it be: running, cycling, squash, football, yoga, knitting, photography, gardening, badminton... (goes off and makes a cup of tea) ... cake sales, charity 5K's, beer tasting, theatre trips, skiing holidays... (goes off for a nap)... 100K walks, Christmas parties, summer parties... You get the idea.
We even have our ow marketplace for buying and selling!
Getting diversity in to STEM subjects is high on the education agenda. We're pleased to say that in many ways we break conventions in Biotech with 50:50 gender split and over 43 nationalities working across our UK & US sites.
Our very own Eva-Lotta Allan, CBO is considered one of the 15 women leading Biotech in Europe.
I have been working at Immunocore full-time (More than a year)
Company genuinely care about employees. Great work environment. Chance to contribute with your work to develop a new, cutting edge therapeutic platform.
Pay could be better considering the cost of life in this area of the country.
I applied through a staffing agency. The process took 4 weeks. I interviewed at Immunocore (Oxford, England) in November 2017.
First interview stage with line manager (1 hour) - competency based interview.
Second stage involved another meeting with the line manager to go into further detail on a couple of key competencies. Then met with 2 Directors (seperately) - going through CV history followed by an informal meeting with the team (total of ~3 hours)